HEM Hemosense

HemoSense, Inc. (AMEX:HEM) today announced that Jim Merselis, President and CEO, will make an investment community presentation at the Lazard Capital Markets Third Annual Life Sciences Conference on Tuesday, November 28 at 2 p.m. Eastern time (11 a.m. Pacific time). The conference is being held at The New York Palace Hotel, New York. A live audio and slide webcast of the presentation will be available via the Internet by visiting the Investors section of the Company�s Web site at www.hemosense.com. An archived presentation will be available on the Web site for 30 days. About HemoSense HemoSense develops, manufactures and markets easy-to-use, handheld blood coagulation systems for monitoring patients taking warfarin. The HemoSense INRatio� system, used by healthcare professionals and patients themselves, consists of a small monitor and disposable test strips. It provides accurate and convenient measurement of blood clotting time, or PT/INR values. Routine measurements of PT/INR are necessary for the safe and effective management of the patient�s warfarin dosing. INRatio is sold in the United States and internationally. For more information, visit www.hemosense.com. HemoSense� and INRatio� are registered trademarks of HemoSense, Inc. HemoSense, Inc. (AMEX:HEM) today announced that Jim Merselis, President and CEO, will make an investment community presentation at the Lazard Capital Markets Third Annual Life Sciences Conference on Tuesday, November 28 at 2 p.m. Eastern time (11 a.m. Pacific time). The conference is being held at The New York Palace Hotel, New York. A live audio and slide webcast of the presentation will be available via the Internet by visiting the Investors section of the Company's Web site at www.hemosense.com. An archived presentation will be available on the Web site for 30 days. About HemoSense HemoSense develops, manufactures and markets easy-to-use, handheld blood coagulation systems for monitoring patients taking warfarin. The HemoSense INRatio(R) system, used by healthcare professionals and patients themselves, consists of a small monitor and disposable test strips. It provides accurate and convenient measurement of blood clotting time, or PT/INR values. Routine measurements of PT/INR are necessary for the safe and effective management of the patient's warfarin dosing. INRatio is sold in the United States and internationally. For more information, visit www.hemosense.com. HemoSense(R) and INRatio(R) are registered trademarks of HemoSense, Inc.